Form 4: Kymera CEO Exercises Options, Sells Shares

Kymera Therapeutics CEO Nello Mainolfi exercised stock options and subsequently sold 30,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Nello Mainolfi, Chief Executive Officer and Director of Kymera Therapeutics, Inc. (KYMR), reported transactions involving the company's common stock.
• On February 25, 2026, Mr. Mainolfi acquired 30,000 shares of common stock by exercising a stock option at a price of $2.08 per share.
• Immediately following the option exercise, Mr. Mainolfi sold a total of 30,000 shares of common stock in multiple transactions.
• The sales occurred at weighted average prices ranging from $89.78 to $93.49 per share.
• Specifically, 19,764 shares were sold at $89.78, 5,434 shares at $90.39, 3,293 shares at $91.76, 1,501 shares at $92.81, and 8 shares at $93.49.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Mainolfi on September 6, 2024.
• Following these transactions, Mr. Mainolfi's direct beneficial ownership of common stock decreased from 696,195 shares to 666,195 shares.
• The exercised stock option was fully vested and exercisable, with an expiration date of November 13, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the transactions were pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling and is a routine part of executive compensation and personal financial management.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, which indicates pre-planning and reduces the perception of opportunistic insider trading.
• The exercise of stock options at a low price ($2.08) and subsequent sale at significantly higher market prices (ranging from $89.78 to $93.49) demonstrates a substantial personal gain for the CEO, reflecting the company's stock appreciation.

Negatives

• The sale of 30,000 shares by the CEO, even if pre-planned, reduces his direct equity stake in the company, which some investors might interpret as a slight negative signal.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice for executives to manage personal liquidity and diversify their portfolios, especially when stock options are deep in the money. These pre-arranged plans help mitigate concerns about executives trading on non-public information.

Related Party Transactions

• The reported transactions are related-party dealings as they involve the CEO of the company exercising stock options and selling shares.

Stakeholder Impact

• Shareholders may view the insider sale with slight caution, but the pre-arranged nature of the 10b5-1 plan generally reduces negative sentiment, as it suggests a planned liquidity event rather than a reaction to new, adverse company developments.

Key Dates

Recommendation

The insider transactions, while involving a sale of shares, were conducted under a pre-arranged 10b5-1 plan. This suggests a planned liquidity event rather than a reaction to new, undisclosed negative information. Therefore, it does not provide a strong signal for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Kymera Therapeutics, KYMR, Nello Mainolfi, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO Transaction